Anti-Lewis Y monoclonal antibody

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAnti-Lewis Y monoclonal antibody
Drug Alias NameHu3S193-RECEPTA-biopharmaRebmAb-100mAb-Hu3S-193- nti-LeYhu3S193
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsLewis-Y antigen modulators
TargetsLewis-Y antigen
Therapy Area/IndicationsFallopian Tube NeoplasmsLung NeoplasmsOvarian Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesBrazil
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInstituto Do Cancer Do Estado De São PauloLudwig Institute For Cancer ResearchRecepta Biopharma Sa
Active IndicationsN/A
Inactive IndicationsFallopian Tube NeoplasmsLung NeoplasmsOvarian Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A